69 144

Cited 2 times in

Optimal duration of DAPT after second-generation drug-eluting stent in acute coronary syndrome

DC FieldValueLanguage
dc.contributor.author고영국-
dc.contributor.author김병극-
dc.contributor.author김중선-
dc.contributor.author신동호-
dc.contributor.author안철민-
dc.contributor.author장양수-
dc.contributor.author최동훈-
dc.contributor.author홍명기-
dc.contributor.author홍성진-
dc.date.accessioned2019-01-15T16:55:23Z-
dc.date.available2019-01-15T16:55:23Z-
dc.date.issued2018-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/166722-
dc.description.abstractBACKGROUND: We evaluated optimal duration of dual antiplatelet therapy (DAPT) after second-generation drug-eluting stent (DES) implantation in acute coronary syndrome (ACS). MATERIAL AND METHODS: From pooled analysis of three randomized clinical trials (EXCELLENT, IVUS-XPL, RESET), a total of 2,216 patient with ACS undergoing second-generation DES implantation were selected. Each study randomized patients to a short-duration DAPT arm (n = 1119; ≤6 months) or a standard-duration DAPT arm (n = 1097; ≥12 months). Two-thirds of patients were male, and their mean age was 63 years. Mean DAPT durations were 164 ±76 and 359 ±68 days, respectively. The primary endpoint was composite of cardiac death, myocardial infarction, stent thrombosis, stroke or major bleeding during the first 12 months after implantation, analyzed according to the intention-to-treat population. RESULTS: Demographic characteristics were balanced between groups. Mean DAPT duration was 164 and 359 days, respectively. Primary endpoint occurred in 22 patients with short-DAPT and 21 patients with standard-DAPT (2.0% versus 1.9%; hazard ratio [HR] 1.03; 95% confidence interval [CI] 0.56-1.86; p = 0.94). Landmark analysis after six-months, no significant difference in primary endpoint between short and standard duration DAPT (1.0% versus 0.8%; HR 1.22; 95% CI 0.51-2.95; p = 0.66). CONCLUSIONS: Short-duration DAPT (≤6 months) demonstrated a similar incidence of net adverse cardiovascular and clinical events at 12 months after second-generation DES in ACS compared with standard duration DAPT (≥12 months). CLINICAL TRIAL REGISTRATION: EXCELLENT (ClinicalTrials.gov, NCT00698607), RESET (ClinicalTrials.gov, NCT01145079), IVUS-XPL (ClinicalTrials.gov, NCT01308281).-
dc.description.statementOfResponsibilityopen-
dc.languageEnglish-
dc.publisherPublic Library of Science-
dc.relation.isPartOfPLOS ONE-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rightshttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.titleOptimal duration of DAPT after second-generation drug-eluting stent in acute coronary syndrome-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.googleauthorJi-Yong Jang-
dc.contributor.googleauthorDong-Ho Shin-
dc.contributor.googleauthorJung-Sun Kim-
dc.contributor.googleauthorSung-Jin Hong-
dc.contributor.googleauthorChul-Min Ahn-
dc.contributor.googleauthorByeong-Keuk Kim-
dc.contributor.googleauthorYoung-Guk Ko-
dc.contributor.googleauthorDonghoon Choi-
dc.contributor.googleauthorMyeong-Ki Hong-
dc.contributor.googleauthorKyung Woo Park-
dc.contributor.googleauthorHyeon-Cheol Gwon-
dc.contributor.googleauthorHyo-Soo Kim-
dc.contributor.googleauthorYangsoo Jang-
dc.identifier.doi10.1371/journal.pone.0207386-
dc.contributor.localIdA00127-
dc.contributor.localIdA00493-
dc.contributor.localIdA00493-
dc.contributor.localIdA00961-
dc.contributor.localIdA00961-
dc.contributor.localIdA02097-
dc.contributor.localIdA02097-
dc.contributor.localIdA02269-
dc.contributor.localIdA02269-
dc.contributor.localIdA03448-
dc.contributor.localIdA03448-
dc.contributor.localIdA04053-
dc.contributor.localIdA04053-
dc.contributor.localIdA04391-
dc.contributor.localIdA04391-
dc.contributor.localIdA04403-
dc.contributor.localIdA04403-
dc.relation.journalcodeJ02540-
dc.identifier.eissn1932-6203-
dc.identifier.pmid30475845-
dc.contributor.alternativeNameKo, Young Guk-
dc.contributor.affiliatedAuthor고영국-
dc.contributor.affiliatedAuthor김병극-
dc.contributor.affiliatedAuthor김병극-
dc.contributor.affiliatedAuthor김중선-
dc.contributor.affiliatedAuthor김중선-
dc.contributor.affiliatedAuthor신동호-
dc.contributor.affiliatedAuthor신동호-
dc.contributor.affiliatedAuthor안철민-
dc.contributor.affiliatedAuthor안철민-
dc.contributor.affiliatedAuthor장양수-
dc.contributor.affiliatedAuthor장양수-
dc.contributor.affiliatedAuthor최동훈-
dc.contributor.affiliatedAuthor최동훈-
dc.contributor.affiliatedAuthor홍명기-
dc.contributor.affiliatedAuthor홍명기-
dc.contributor.affiliatedAuthor홍성진-
dc.contributor.affiliatedAuthor홍성진-
dc.citation.volume13-
dc.citation.number11-
dc.citation.startPagee0207386-
dc.identifier.bibliographicCitationPLOS ONE, Vol.13(11) : e0207386, 2018-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.